Extending outpatient medical abortion services through 70 days of gestational age
- PMID:23090524
- DOI: 10.1097/aog.0b013e31826c315f
Extending outpatient medical abortion services through 70 days of gestational age
Abstract
Objective: To estimate the efficacy and acceptability of medical abortion at 64-70 days from last menstrual period (LMP) and to compare it with the already proven 57-63 days from LMP gestational age range.
Methods: This prospective, comparative, open-label trial enrolled 729 women with pregnancies 57-70 days from LMP requesting abortion at six U.S. clinics. Medical abortions were managed with 200 mg mifepristone and 800 micrograms buccal misoprostol and sites' service delivery protocols. Follow-up visits occurred 7-14 days after mifepristone, with an abortion considered complete if surgical intervention was not performed. Success, ongoing pregnancy, and acceptability rates were compared.
Results: A total of 629 cases were analyzable for efficacy. Success rates were similar in the two groups (57-63 days group: 93.5%, 95% confidence interval [CI] 90-96; 64-70 days group: 92.8%, 95% CI 89-95). Ongoing pregnancy rates also did not differ significantly (57-63 days: 3.1%, 95% CI 1.6-5.8; 64-70 days: 3.0%, 95% CI 1.5-5.7). Acceptability was high and similar in both arms, with most women (57-63 days: 87.4%; 64-70 days: 88.3%) reporting that their experience was either very satisfactory or satisfactory.
Conclusion: Medical abortion with mifepristone and misoprostol in current outpatient settings is an efficacious and acceptable method of ending pregnancies 64-70 days from LMP and can be offered without alteration of existing services.
Clinical trial registration: clinicaltrials.gov, www.clinicaltrials.gov,NCT00997347.
Level of evidence: II.
Similar articles
- A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: a prospective comparative open-label trial.Bracken H, Dabash R, Tsertsvadze G, Posohova S, Shah M, Hajri S, Mundle S, Chelli H, Zeramdini D, Tsereteli T, Platais I, Winikoff B.Bracken H, et al.Contraception. 2014 Mar;89(3):181-6. doi: 10.1016/j.contraception.2013.10.018. Epub 2013 Nov 12.Contraception. 2014.PMID:24332431Clinical Trial.
- Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.Baird DT, Sukcharoen N, Thong KJ.Baird DT, et al.Hum Reprod. 1995 Jun;10(6):1521-7. doi: 10.1093/humrep/10.6.1521.Hum Reprod. 1995.PMID:7593528Clinical Trial.
- Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S.Schaff EA, et al.Contraception. 1999 Jan;59(1):1-6. doi: 10.1016/s0010-7824(98)00150-4.Contraception. 1999.PMID:10342079Clinical Trial.
- Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions.Newhall EP, Winikoff B.Newhall EP, et al.Am J Obstet Gynecol. 2000 Aug;183(2 Suppl):S44-53. doi: 10.1067/mob.2000.107950.Am J Obstet Gynecol. 2000.PMID:10944369Review.
- Flexible mifepristone and misoprostol administration interval for first-trimester medical termination.Wedisinghe L, Elsandabesee D.Wedisinghe L, et al.Contraception. 2010 Apr;81(4):269-74. doi: 10.1016/j.contraception.2009.09.007. Epub 2009 Oct 29.Contraception. 2010.PMID:20227541Review.
Cited by
- Medical abortion in the late first trimester: a systematic review.Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI.Kapp N, et al.Contraception. 2019 Feb;99(2):77-86. doi: 10.1016/j.contraception.2018.11.002. Epub 2018 Nov 13.Contraception. 2019.PMID:30444970Free PMC article.
- Abortion Surveillance - United States, 2019.Kortsmit K, Mandel MG, Reeves JA, Clark E, Pagano HP, Nguyen A, Petersen EE, Whiteman MK.Kortsmit K, et al.MMWR Surveill Summ. 2021 Nov 26;70(9):1-29. doi: 10.15585/mmwr.ss7009a1.MMWR Surveill Summ. 2021.PMID:34818321Free PMC article.
- Gestational dating using last menstrual period and bimanual exam for medication abortion in pharmacies and health centers in Nepal.Averbach S, Puri M, Blum M, Rocca C.Averbach S, et al.Contraception. 2018 Oct;98(4):296-300. doi: 10.1016/j.contraception.2018.06.004. Epub 2018 Jun 21.Contraception. 2018.PMID:29936150Free PMC article.
- Advantages and Disadvantages of Medical Abortion, According to Brazilian Residents in Obstetrics and Gynaecology.Bento SF, Pádua KS, Pacagnella RC, Fernandes KG, Osis MJD, Duarte GA, Faúndes A.Bento SF, et al.Rev Bras Ginecol Obstet. 2020 Dec;42(12):793-799. doi: 10.1055/s-0040-1718952. Epub 2020 Dec 21.Rev Bras Ginecol Obstet. 2020.PMID:33348395Free PMC article.
- Abortion Surveillance - United States, 2018.Kortsmit K, Jatlaoui TC, Mandel MG, Reeves JA, Oduyebo T, Petersen E, Whiteman MK.Kortsmit K, et al.MMWR Surveill Summ. 2020 Nov 27;69(7):1-29. doi: 10.15585/mmwr.ss6907a1.MMWR Surveill Summ. 2020.PMID:33237897Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials